tiprankstipranks
Viridian Therapeutics price target raised to $34 from $27 at H.C. Wainwright
The Fly

Viridian Therapeutics price target raised to $34 from $27 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $27 and keeps a Buy rating on the shares. The firm expects veligrotug to meet the endpoints in chronic thyroid eye given that Tepezza demonstrated efficacy in chronic TED treatment. It thinks veligrotug will show at least comparable efficacy to Tepezza.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App